AbbVie 2014 Annual Report Download - page 160

13NOV201221352027
(c) These are the shares of performance-vested restricted stock that remained outstanding and unvested on
December 31, 2014, from an award made on February 20, 2014. The award has a 5-year term, with no more
than one-third of the original award vesting in any one year upon AbbVie achieving a minimum return on
equity target, measured at the end of the relevant year. In 2014, AbbVie reached its minimum return on
equity target and one-third of the unvested shares vested on February 27, 2015.
(d) These are the shares of performance-vested restricted stock that remained outstanding and unvested on
December 31, 2014, from an award made on June 2, 2014. The award has a 5-year term, with no more than
one-third of the original award vesting in any one year upon AbbVie achieving a minimum return on equity
target.
(e) These are the shares of performance-vested restricted stock that remained outstanding and unvested on
December 31, 2014, from an award made on December 1, 2012. These shares will vest after January 1, 2016
subject to continued employment with AbbVie through the vesting date and AbbVie achieving a minimum
return on equity target for the period 2013 through 2015.
2014 Option Exercises and Stock Vested
................................................................................................................................................................................................................................................................................................................................................................................................
The following table summarizes for each NEO the number of shares acquired on the exercise of AbbVie stock
options and the number of shares acquired on the vesting of AbbVie stock awards in 2014:
R. Gonzalez 0 $0 118,774 $6,046,784
M. Severino 0 0 0 0
C. Alban 0 0 38,633 1,966,806
L. Schumacher 8,928 67,139 52,110 2,652,920
W. Chase 8,495 373,159 27,033 1,376,250
Pension Benefits
................................................................................................................................................................................................................................................................................................................................................................................................
During 2014, the NEOs participated in two AbbVie-sponsored defined benefit pension plans: the AbbVie Pension
Plan, a tax-qualified pension plan; and the AbbVie Supplemental Pension Plan, a non-qualified supplemental pension
plan. The Supplemental Pension Plan also includes a benefit feature AbbVie uses to attract senior executives who are
mid-career hires, which provides an additional benefit to such participants that is less valuable to participants who have
spent most of their career at the company. Except as provided in AbbVie’s change in control agreements, AbbVie does
not have a policy granting extra years of credited service under the plans. The change in control agreements are
described in the section of this proxy statement captioned ‘‘Potential Payments upon Termination or Change in Control.’’
The compensation considered in determining the pensions payable to the NEOs is the compensation shown in
the ‘‘Salary’’ and ‘‘Non-Equity Incentive Plan Compensation’’ columns of the Summary Compensation Table.
Pension Plan
The Pension Plan covers most AbbVie employees in the United States, age 21 or older, and provides participants
with a life annuity benefit at normal retirement equal to A plus the greater of B or C below.
A. 1.10% of 5-year final average earnings multiplied by years of benefit service after 2003.
40 2015 Proxy Statement
Option Awards Stock Awards
Number of Number of
Shares Value Shares Value
Acquired On Realized On Acquired On Realized On
Name Exercise (#) Exercise ($) Vesting (#) Vesting ($)
EXECUTIVE COMPENSATION